Combination drug treatment before surgery for advanced head and neck cancer
Part of Cancer clinical trials.
This study tests two drugs (pertuzumab and lenvatinib) given together before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve outcomes for patients who haven't received prior cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced head and neck squamous cell carcinoma (stage III or IV) that has not been treated with chemotherapy or radiation before
- You are between 18 and 75 years old
- You have at least one measurable tumor visible on imaging
- Your body can handle the treatment (good heart, liver, kidney, and blood cell function)
- You are willing to use birth control during treatment and for 6 months after if you can have children
- You do not have a history of other cancers in the past 5 years (except skin cancer or thyroid cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (one targeted therapy and one immunotherapy) plus standard chemotherapy before surgery for head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of targeted immunotherapy and chemotherapy given before surgery or radiation for head and neck cancer. The goal is to shrink the tumor and potentially improve outcomes.
This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests a combination of two immunotherapy drugs (pembrolizumab and N-803) with or without special immune cells (PD-L1 t-haNK cells) before surgery for head and neck cancer. The goal is to see if this treatment can shrink the cancer or improve the outcome after surgery.
This trial is testing a combination of two drugs (becotatug vedotin and pucotenlimab) given before surgery to shrink recurrent head and neck cancer that has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this approach helps make the tumor removable and improves outcomes.
Hear when a new Squamous Cell Carcinoma of the Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.